HaloVax

HaloVax is a clinical-stage biotechnology company focused on developing personalized immunotherapy treatments for aggressive cancers, with a primary focus on glioblastoma multiforme (GBM). The company's core technology utilizes a proprietary dendritic cell-based vaccine platform designed to stimulate a robust immune response against tumor-associated antigens. By leveraging patient-specific tumor data, HaloVax aims to provide targeted therapies that improve survival outcomes and quality of life for patients with limited treatment options. The company is currently advancing its lead candidate through early-phase clinical trials to demonstrate safety and preliminary efficacy in neuro-oncology.